Drug Overview
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3. Preclinical studies have shown the role of PDGF in modulating angiogenesis, and have demonstrated that inhibition of both PDGF and VEGF results in reduced tumor vascularization and greater growth inhibition.
Sutent’s annual sales peaked in 2012 at $1.2bn and have been declining since. Further sales decline of the drug within the renal cell carcinoma (RCC) market is expected with the arrival of more efficacious combination therapies and imminent patent expiries. Sutent was considered the standard of care in the first line, and as such many clinical trials used Sutent as the active comparator and subsequently showed the superiority of newer regimens. This wealth of clinical trial data will negatively impact sales of Sutent for use in the first line, although revenues will be somewhat protected by physician familiarity and the drug’s recent label expansion in the US to include use in the adjuvant setting. However, a sharp decline in sales is expected upon patent expiry in the US (2021), EU (2021), and Japan (2024).
Analyst Outlook
Sutent’s (sunitinib; Pfizer) annual sales peaked in 2012 at $1.2bn and have been declining since. Further sales decline of the drug within the renal cell carcinoma (RCC) market is expected with the arrival of more efficacious combination therapies and imminent patent expiries. Sutent was considered the standard of care in the first line, and as such many clinical trials used Sutent as the active comparator and subsequently showed the superiority of newer regimens. This wealth of clinical trial data will negatively impact sales of Sutent for use in the first line, although revenues will be somewhat protected by physician familiarity and the drug’s recent label expansion in the US to include use in the adjuvant setting. However, a sharp decline in sales is expected upon patent expiry in the US (2021), EU (2021), and Japan (2024).
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3. Preclinical studies have shown the role of PDGF in modulating angiogenesis, and have demonstrated that inhibition of both PDGF and VEGF results in reduced tumor vascularization and greater growth inhibition.
Sutent’s annual sales peaked in 2012 at $1.2bn and have been declining since. Further sales decline of the drug within the renal cell carcinoma (RCC) market is expected with the arrival of more efficacious combination therapies and imminent patent expiries. Sutent was considered the standard of care in the first line, and as such many clinical trials used Sutent as the active comparator and subsequently showed the superiority of newer regimens. This wealth of clinical trial data will negatively impact sales of Sutent for use in the first line, although revenues will be somewhat protected by physician familiarity and the drug’s recent label expansion in the US to include use in the adjuvant setting. However, a sharp decline in sales is expected upon patent expiry in the US (2021), EU (2021), and Japan (2024).
Analyst Outlook
Sutent’s (sunitinib; Pfizer) annual sales peaked in 2012 at $1.2bn and have been declining since. Further sales decline of the drug within the renal cell carcinoma (RCC) market is expected with the arrival of more efficacious combination therapies and imminent patent expiries. Sutent was considered the standard of care in the first line, and as such many clinical trials used Sutent as the active comparator and subsequently showed the superiority of newer regimens. This wealth of clinical trial data will negatively impact sales of Sutent for use in the first line, although revenues will be somewhat protected by physician familiarity and the drug’s recent label expansion in the US to include use in the adjuvant setting. However, a sharp decline in sales is expected upon patent expiry in the US (2021), EU (2021), and Japan (2024).
Table of Contents
OVERVIEW- Drug Overview
- Product Profiles
- Sutent: Renal cell carcinoma (RCC)
LIST OF FIGURES
Figure 1: Sutent for RCC – SWOT analysis
Figure 2: The author's drug assessment summary of Sutent for RCC
Figure 3: The author's drug assessment summary of Sutent for RCC
Figure 4: Sutent sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Sutent drug profile
Table 2: Sutent pivotal trial data in RCC
Table 3: Sutent Phase III data in RCC
Table 4: Sutent sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
